Program
SHR-3045
A development code. Also written as “SHR-3045 Injection”.
In Jiangsu HengRui Medicine's pipeline, PD-1
. Its studies are mostly in Arthritis, Rheumatoid, led by Jiangsu HengRui Medicine.
Furthest: phase 2, since Nov 13, 20253 company-led studies, 1 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 31 open or running | phase 2since Nov 13, 2025 | Mar 13, 2025 | none ahead |
- Named in Jiangsu HengRui Medicine’s own pipeline as
SHR-3045
, phase 2, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 13, 2025First study: phase 1 study in Arthritis, RheumatoidFirst studyNCT06883695 · 40 enrolled · China
- Sep 23, 2025Phase 1 study in Arthritis, RheumatoidNCT07200596 · 16 enrolled · China
- Nov 13, 2025Phase 2 study in Moderate to Severe Active Rheumatoid ArthritisNCT07233655 · 30 enrolled · China
TargetBeta
“PD-1”the company's pipeline, read by Claude · source
Other programs on PDCD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| tivunatamig | Pfizer | phase 3 | 15 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| pucotenlimabrule | taizhou-hanzhong-biomedical-co-ltd | phase 3 | 15 |
| enlonstobartrule | CSPC Pharmaceutical Group | phase 3 | 15 |
| ezabenlimab | Boehringer Ingelheim | phase 3 | 13 |
| Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363rule | Innovent Biologics | phase 3 | 10 |
| rulonilimabrule | Lunan Pharmaceutical Group | phase 3 | 9 |
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 4 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07233655Moderate to Severe Active Rheumatoid Arthritis · China | 2 | Active, not recruiting | Apr 21, 2026 | 30 |
| NCT07200596Arthritis, Rheumatoid · China | 1 | Completed | Mar 31, 2026 | 16 |
| NCT06883695Arthritis, Rheumatoid · China | 1 | Completed | Jun 17, 2025 | 40 |
How it is read
Names in the registry
- “SHR-3045 Injection”, 3 entries
Codes read as this program: SHR3045.
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.